Table 1:
Patient | Age | Gender | Histology | Cohort | No. of prior systemic therapies | Prior VEGF therapy (Y/N) |
---|---|---|---|---|---|---|
1 | 72 | Female | Ovarian carcinoma | High | 6 | N |
2 | 57 | Female | Lung carcinoma | High | 4 | Y |
3 | 57 | Female | Breast carcinoma | Low | 6 | N |
4 | 47 | Female | Thyroid carcinoma | High | 1 | Y |
5 | 64 | Female | Urothelial carcinoma | High | 2 | N |
6 | 71 | Male | Squamous cell carcinoma | Low | 4 | N |
7 | 65 | Female | Lung carcinoma | Low | 1 | N |
8 | 67 | Male | Lung carcinoma | Low | 2 | N |
9 | 54 | Female | Ovarian carcinoma | Low | 2 | N |
10 | 67 | Female | Endometrial carcinoma | High | 5 | N |
11 | 56 | Female | Breast carcinoma | Low | 11 | N |
12 | 65 | Male | Adenoid cystic carcinoma | Low | 0 | N |
13 | 53 | Male | Leiomyosarcoma | Low | 3 | N |
14 | 58 | Male | Unknown primary carcinoma | High | 0 | N |